Percutaneous therapy of soft tissue rheumatic diseases. Clinical trials of the non-steroid anti-phlogistic agent Rheumon gel
Podzich, M.
ZFA. Zeitschrift für Allgemeinmedizin 58(16): 921-924
1982
ISSN/ISBN: 1433-6251 PMID: 7051600 Document Number: 5594
Document emailed within 1 workday
Related Documents
De Arcangelis, A. 1971: On the use in anti-rheumatic therapy of a new non-steroid anti-inflammatory agent: glucosamide of monohydrated (N-p-chloro-benzoyl-2-methyl-5-methoxy)-indol-3-acetic acid La Clinica Terapeutica 59(3): 229-239Accardo, S.; Traverso, A.; Caraffa, M.; Ferretti, A.; Moreno, M. 1978: Use of a new non-steroid, anti-inflammatory drug, ketoprofen, in the therapy of rheumatic diseases Minerva Medica 69(51): 3523-3530
Labhardt, F.; Müller, W. 1979: Psychosomatic aspects of rheumatic diseases. With special reference to "soft tissue reheumatism" Medizinische Klinik 74(21): 802-811
da Silva, L.C.; Sette, H.; Chamone, D.A.; Sáez-Alquezar, A.; Punskas, J.A.; Raia, S. 1975: Further clinical trials with oxamniquine (UK 4271), a new anti-schistosomal agent Revista do Instituto de Medicina Tropical de Sao Paulo 17(5): 307-311
Scheinberg, M.A. 1988: Clinical trials with biological response modifiers in rheumatic diseases Journal of Rheumatology 15(7): 1056-1057
Motohiro, T.; Tanaka, K.; Koga, T.; Shimada, Y.; Tomita, N.; Nishiyama, T.; Ishimoto, K.; Tominaga, K.; Iriki, T.; Harada, M. 1985: Clinical trials of BRL 25000 (clavulanic acid-amoxicillin) granules on skin and soft tissue infections in the field of pediatrics Japanese Journal of Antibiotics 38(2): 507-537
Kurucz, I.; Németh, K.; Mészáros, S.; Török, K.; Nagy, Z.; Zubovics, Z.; Horváth, K.; Bodor, N. 2004: Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid Die Pharmazie 59(5): 412-416
Koch, G.; Mertelsmann, R.; Stein, E.; Kastendieck, H.; Bartscherer, M. 1978: Malignant tumors of the soft tissue and the peripheral nervous system (soft tissue sarcomas). Current aspects of diagnosis and therapy Die Medizinische Welt 29(1): 31-34
Ginesu, F.; Schena, G.; Polo, F.; Deiola, G.; Ortu, A.R. 1983: Controlled clinical study of the clinical efficacy and tolerability of a new nonsteroidal anti-inflammatory preparation, imidazole-2-hydroxybenzoate, in patients with pain and phlogistic syndromes of varying etiopathogenesis Bollettino Chimico Farmaceutico 122(12): 37S-49S
Chogle, A.R. 2002: Clinical significance of anti-Ro/SS-A and anti-La/SS-B autoantibodies in various connective tissue diseases Journal of the Association of Physicians of India 50: 759-761
Takeuchi, S.; Akahoshi, Y.; Kasai, C.; Nishimoto, Y. 1984: Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors Gan no Rinsho. Japan Journal of Cancer Clinics 30(9 Suppl): 1113-1122
Simon, B.; Leucht, U.; Amon, I.; Brandau, J.; Müller, P. 1993: Nizatidine in therapy and prevention of non-steroidal anti-rheumatic drug-induced ulcers in rheumatic patients Zeitschrift für Gastroenterologie 31(6): 395-400
Sun, Y.-H.; Jia, C.-S.; Wang, J.-L.; Gang, W.-J.; Li, X.-F.; Zhang, X.-X.; Liu, X.; Du, Y.-Z. 2013: Exploration on the application characteristics of bloodletting therapy for the diseases relevant with soft tissue infection by data mining technology Zhongguo Zhen Jiu 33(9): 803-807
Davis, T.; Gore-Langton, R.E.; Cheson, B.D. 2000: Clinical trials referral resource. Current clinical trials of the anti-CD20 monoclonal antibody rituximab Oncology 14(10): 1437; 1440-1443
Thomas, J.W.; Vertkin, A.; Nell, L.J. 1987: Antiinsulin antibodies and clinical characteristics of patients with systemic lupus erythematosus and other connective tissue diseases with steroid induced diabetes Journal of Rheumatology 14(4): 732-735
Chieli, T.; Fregnan, G.B.; Frigerio, L.; Vidali, M. 1976: Toxicity and collateral pharmacological effects of a 3: a new non-steroid anti-inflammatory agent Bollettino Chimico Farmaceutico 115(1): 41-57
Netti, C.; Bandi, G.L.; Pecile, A. 1972: Anti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compounds Il Farmaco; Edizione Pratica 27(8): 453-466
Iakovlev, V.P.; Krutikov, M.G.; Blatun, L.A.; Izotova, G.N.; Grishina, I.A. 2000: Clinical and laboratory efficacy of the novel difluoroquinolone Sparflo (sparfloxacin) in therapy of skin and soft tissue infections Antibiotiki i Khimioterapiia 45(12): 37-40
Kullich, W.; Fromme, K.; Klein, G. 1996: Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases Wiener Medizinische Wochenschrift 146(17): 459-464
Gachályi, B.; Vas, A.; Káldor, A. 1984: Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver International Journal of Clinical Pharmacology Therapy and Toxicology 22(7): 353-354